Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013 PR Newswire NANJING, China, April 26, 2013 NANJING, China, April 26, 2013 /PRNewswire/ --Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, May 9, at 8 p.m. Beijing/Hong Kong time). To access the conference call, please dial: International toll: +65.6723.9381 United States toll-free: +1.866.519.4004 United States toll: +1.718.354.1231 China Domestic toll: 800.819.0121 China Domestic mobile toll: 400.620.8038 Hong Kong toll: +852.2475.0994 Please ask to be connected to Q1 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 58031483. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com. Following the earnings conference call, an archive of the call will be available by dialing: United States toll-free: +1. 855.452.5696 United States toll: +1. 646.254.3697 The passcode for replay participants is 58031483. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement. About Simcere Pharmaceutical Group Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com. Investor and Media Contacts: Email: email@example.com In Nanjing: In the United States: Jie Liu D'Elia Cindy Zheng Vice President Brunswick Simcere Pharmaceutical Group Group Tel: Tel: 86-25-8556-6666*8857 1-212-333-3810 In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600 SOURCE Simcere Pharmaceutical Group Website: http://www.simcere.com
Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
Press spacebar to pause and continue. Press esc to stop.